… satisfactorily to long-acting inhaled bronchodilator(s). In … the assessment of patients, risk
prediction, treatment guidance and … to patients with airway eosinophils of >3% with stable COPD.…

… count (BEC), which predicts the magnitude of the effect of … ICS to long-acting bronchodilators
in patients with COPD and … process even in patients with stable COPD [Citation40]. In …

… in sera of patients with stable COPD and their associations … ), long-acting β 2 agonist (LABA)
or long-acting muscarinic … In addition, we wanted to evaluate predictive performance of lipid …

… In a post hoc economic analysis of EMAX data using the validated GALAXY model, UMEC/VI
was predicted to be the most cost-effective treatment option versus either monotherapy …

… are often combined with long-acting bronchodilators. To the … to assess their performances
in stable COPD due to the already … Can we predict the prognosis of COPD with a routine blood …

… In order to include patients with stable COPD at enrolment, … Overall, long-acting bronchodilators
were more widely used … eosinophil counts to predict better response to ICS therapy. …

… In stable COPD patients, an elevated NLR is associated with … long-acting muscarinic antagonist
(LAMA), and a long-acting … and COPD patients with a significant bronchodilator response …

… maintenance long-acting bronchodilator therapy, except in people … be considered in people
with stable COPD and hypercapnia (… A history of COPD exacerbations is the best predictor of …

… bronchodilators (BDs) alone, whereas in patients with COPD, long-acting muscarinic antagonists
or long-acting β… was lower for COPD, whereas for ΔFVC >10% predicted, the proportion …

… COPD include bronchodilators, mainly long-acting muscarinic receptor antagonists (LAMA)
and long-acting … for the management of most stable COPD patients will remain anchored to …